Development of Polymeric Nanoparticles for Blood–Brain Barrier Transfer—Strategies and Challenges

Advanced Science, Год журнала: 2021, Номер 8(10)

Опубликована: Март 7, 2021

Neurological disorders such as Alzheimer's disease, stroke, and brain cancers are difficult to treat with current drugs their delivery efficacy the is severely hampered by presence of blood-brain barrier (BBB). Drug systems have been extensively explored in recent decades aiming circumvent this barrier. In particular, polymeric nanoparticles shown enormous potentials owing unique properties, high tunability, ease synthesis, control over drug release profile. However, careful analysis performance effective transport across BBB should be performed using clinically relevant testing models. review, nanoparticle for central nervous system discussed an emphasis on effects particle size, shape, surface modifications penetration. Moreover, authors critically analyze vitro vivo models used evaluate penetration efficacy, including latest developments BBB-on-a-chip Finally, challenges future perspectives development combat neurological discussed.

Язык: Английский

---

Tumor-derived exosomes in the regulation of macrophage polarization

Inflammation Research, Год журнала: 2020, Номер 69(5), С. 435 - 451

Опубликована: Март 11, 2020

Язык: Английский

---

Frontiers in the treatment of glioblastoma: Past, present and emerging

Advanced Drug Delivery Reviews, Год журнала: 2021, Номер 171, С. 108 - 138

Опубликована: Янв. 22, 2021

Язык: Английский

---

EGFR signaling pathway as therapeutic target in human cancers

Seminars in Cancer Biology, Год журнала: 2022, Номер 85, С. 253 - 275

Опубликована: Апрель 12, 2022

Язык: Английский

---

Engineered Nanoparticles for Cancer Vaccination and Immunotherapy

Accounts of Chemical Research, Год журнала: 2020, Номер 53(10), С. 2094 - 2105

Опубликована: Окт. 5, 2020

ConspectusThe immune system has evolved over time to protect the host from foreign microorganisms. Activation of is predicated on a distinction between self and nonself. Unfortunately, cancer characterized by genetic alterations in host's cells, leading uncontrolled cellular proliferation evasion surveillance. Cancer immunotherapy aims educate not only recognize but also attack kill mutated cells. While checkpoint blockers have been proven be effective against multiple types advanced cancer, overall patient response rate still remains below 30%. Therefore, there an urgent need improve current immunotherapies. In this Account, we present overview our recent progress nanoparticle-based strategies for improving vaccines We other complementary give well-rounded snapshot field combination immunotherapy. The versatility tunability nanoparticles make them promising platforms addressing individual challenges posed various cancers. For example, can deliver cargo materials specific such as delivered antigen-presenting cells strong activation. Nanoparticles allow stimuli-responsive delivery therapeutics thus forming basis Here, focus nanoparticle engineered tumor antigens, whole chemotherapeutic or phototherapeutic agents manner effectively safely trigger each work, discuss platform developed, synthesis chemistry, vivo applications. Nanovaccines offer unique codelivery personalized neoantigens adjuvants elicitation robust responses aggressive tumors. either delivering cell lysate formed may increase repertoire antigens targets while exploiting immunogenic death prime antitumor responses. how antigen- cell-based approaches open door vaccination On hand, chemotherapy, phototherapy, radiotherapy are more standardized therapies, promote their ability initiate T activation efficacy with minimal toxicity. Finally, building immunotherapy, should set ultimate goal clinical translation efficacy. will regulatory, analytical, manufacturing hurdles that addressed expedite nanomedicine-based

Язык: Английский

---

PD-L1/PD-1 Axis in Glioblastoma Multiforme

International Journal of Molecular Sciences, Год журнала: 2019, Номер 20(21), С. 5347 - 5347

Опубликована: Окт. 28, 2019

Glioblastoma (GBM) is the most popular primary central nervous system cancer and has an extremely expansive course. Aggressive tumor growth correlates with short median overall survival (OS) oscillating between 14 17 months. The rate of patients in a three-year follow up oscillates around 10%. interaction proteins programmed death-1 (PD-1) cell death ligand (PD-L1) creates immunoregulatory axis promoting invasion glioblastoma multiforme cells brain tissue. PD-1 pathway maintains immunological homeostasis protects against autoimmunity. PD-L1 expression on surface promotes receptor activation microglia, resulting negative regulation T responses. induce secretion by various receptors such as toll like (TLR), epidermal factor (EGFR), interferon alpha (IFNAR), interferon-gamma (IFNGR). Binding to activates protein tyrosine phosphatase SHP-2, which dephosphorylates Zap 70, this inhibits proliferation downregulates lymphocyte cytotoxic activity. Relevant studies demonstrated that glioma WHO grading could be considered biomarker. Studies preclinical GBM mouse models confirmed safety efficiency monoclonal antibodies targeting PD-1/PD-L1 axis. Satisfactory results significant regression mass longer animal time were observed. Monoclonal inhibiting are being tested clinical trials concerning recurrent multiforme.

Язык: Английский

---

EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment

Nature Reviews Clinical Oncology, Год журнала: 2021, Номер 19(1), С. 51 - 69

Опубликована: Сен. 24, 2021

Язык: Английский

---

Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders

Molecules, Год журнала: 2020, Номер 25(8), С. 1929 - 1929

Опубликована: Апрель 21, 2020

Although the global prevalence of neurological disorders such as Parkinson's disease, Alzheimer's glioblastoma, epilepsy, and multiple sclerosis is steadily increasing, effective delivery drug molecules in therapeutic quantities to central nervous system (CNS) still lacking. The blood brain barrier (BBB) major obstacle for entry drugs into brain, it comprises a tight layer endothelial cells surrounded by astrocyte foot processes that limit drugs' entry. In recent times, intranasal has emerged reliable method bypass BBB treat diseases. route with both solution particulate formulations been demonstrated repeatedly preclinical models, including human trials. key features determining efficacy via include olfactory area nares, longer retention time at nasal mucosal surface, enhanced penetration through epithelia, reduced metabolism cavity. This review describes important disorders, challenges disordered CNS, new techniques designed overcome these facilitate more efficient targeted delivery. potential treatment possibilities transfer will increase development devices.

Язык: Английский

---

Role of glioblastoma stem cells in cancer therapeutic resistance: a perspective on antineoplastic agents from natural sources and chemical derivatives

Stem Cell Research & Therapy, Год журнала: 2021, Номер 12(1)

Опубликована: Март 24, 2021

Abstract Glioblastoma (GBM) is the highest-grade form of glioma, as well one most aggressive types cancer, exhibiting rapid cellular growth and highly invasive behavior. Despite significant advances in diagnosis therapy recent decades, outcomes for high-grade gliomas (WHO grades III-IV) remain unfavorable, with a median overall survival time 15–18 months. The concept cancer stem cells (CSCs) has emerged provided new insight into GBM resistance management. CSCs can self-renew initiate tumor are also responsible cell heterogeneity induction systemic immunosuppression. idea that could be dependent on innate differences sensitivity clonogenic glial (GSCs) to chemotherapeutic drugs/radiation prompted scientific community rethink understanding therapies directed at eliminating these or modulating their stemness. This review aims describe major intrinsic extrinsic mechanisms mediate chemoradioresistant GSCs based antineoplastic agents from natural sources, derivatives, synthetics used alone synergistic combination conventional treatment. We will address ongoing clinical trials focused promising targets. Although development effective remains challenge molecular oncology, GSC knowledge offer directions future.

Язык: Английский

---

Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM)

Cancers, Год журнала: 2023, Номер 15(7), С. 2116 - 2116

Опубликована: Апрель 1, 2023

Glioblastoma multiforme (GBM) is a highly aggressive form of brain cancer that difficult to treat due its resistance both radiation and chemotherapy. This largely the unique biology GBM cells, which can evade effects conventional treatments through mechanisms such as increased cell death rapid regeneration cancerous cells. Additionally, blood–brain barrier makes it for chemotherapy drugs reach leading reduced effectiveness. Despite these challenges, there are several treatment options available GBM. The standard care newly diagnosed patients involves surgical resection followed by concurrent chemoradiotherapy adjuvant Emerging include immunotherapy, checkpoint inhibitors, targeted therapies, bevacizumab, attempt attack specific vulnerabilities in Another promising approach use tumor-treating fields, type electric field therapy has been shown slow growth Clinical trials ongoing evaluate safety efficacy other innovative GBM, intending improve with outcomes patients.

Язык: Английский

---